Skip to main content
Fig. 2 | BMC Cardiovascular Disorders

Fig. 2

From: Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis

Fig. 2

Patients categorized under WHO functional classification after treatment with ambrisentan (ITT population-LOCF): post-hoc analysis of CTD-PAH and IPAH/HPAH sub-groups. CTD, connective tissue disease; HPAH, Heritable PAH; IPAH, Idiopathic PAH; ITT, intent-to-treat; LOCF, last observation carried forward; PAH, pulmonary arterial hypertension; WHO, World Health Organisation

Back to article page
\